Value Discussion Reemerges at NICE: Roche's Gazyvaro Rejected
Following Kadcyla, NICE has now rejected another drug from Roche: Gazyvaro for CLL, citing ambiguities in the company's filing and the high cost.
Another new cancer drug from Roche, this time for treating leukaemia, has been rejected by Britain's healthcare cost-effectiveness agency NICE on the grounds that data about its value is uncertain.
In August the National Institute for Health and Care Excellence (NICE) rejected the Swiss drugmaker's drug Kadcyla for an aggressive form of breast cancer. Roche had proposed a discount for that drug, which carries a full list price of more than 90,000 pounds for a course of treatment.
Friday's decision promises to further sour relations between NICE and the world's biggest maker of cancer drugs, which two months ago said NICE was "not fit for purpose".
Read the report on Reuters:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
Promising Early Efgartigimod Response Data for Generalized Myasthenia GravisSeptember 18th 2025
Iron Dysregulation Linked to MS Progression, Review FindsSeptember 18th 2025
Metabolic Issues More Common in Patients With HIVSeptember 18th 2025
Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction RateSeptember 18th 2025
